View in EDS

miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.

Saved in:
Bibliographic Details
Title: miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.
Authors: Santos AA; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal. Electronic address: afasantos@ff.ulisboa.pt., Pires D; CIIS - Centro de Investigação Interdisciplinar em Saúde, Faculdade de Medicina, Universidade Católica Portuguesa, Lisboa, Portugal., Marques V; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal., Alesina N; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal., Rodrigues PM; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Bravo AC; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Gouveia C; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Saraiva S; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Correia L; Division of Gastroenterology, ULS Santa Maria, Lisboa, Portugal., Crespo R; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal., da Silva JP; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal., Cravo M; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal., Banales JM; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain., Torres J; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal; Faculdade de Medicina, Universidade de Lisboa, Portugal., Rodrigues CMP; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Source: Experimental and molecular pathology [Exp Mol Pathol] 2026 Mar; Vol. 145, pp. 105013. Date of Electronic Publication: 2025 Dec 05.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370711 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0945 (Electronic) Linking ISSN: 00144800 NLM ISO Abbreviation: Exp Mol Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41352234
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Santos+AA%22">Santos AA</searchLink>; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal. Electronic address: afasantos@ff.ulisboa.pt.<br /><searchLink fieldCode="AU" term="%22Pires+D%22">Pires D</searchLink>; CIIS - Centro de Investigação Interdisciplinar em Saúde, Faculdade de Medicina, Universidade Católica Portuguesa, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Marques+V%22">Marques V</searchLink>; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Alesina+N%22">Alesina N</searchLink>; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Rodrigues+PM%22">Rodrigues PM</searchLink>; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Bravo+AC%22">Bravo AC</searchLink>; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.<br /><searchLink fieldCode="AU" term="%22Gouveia+C%22">Gouveia C</searchLink>; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.<br /><searchLink fieldCode="AU" term="%22Saraiva+S%22">Saraiva S</searchLink>; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.<br /><searchLink fieldCode="AU" term="%22Correia+L%22">Correia L</searchLink>; Division of Gastroenterology, ULS Santa Maria, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Crespo+R%22">Crespo R</searchLink>; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22da+Silva+JP%22">da Silva JP</searchLink>; Division of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Cravo+M%22">Cravo M</searchLink>; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Banales+JM%22">Banales JM</searchLink>; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Torres+J%22">Torres J</searchLink>; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal; Faculdade de Medicina, Universidade de Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Rodrigues+CMP%22">Rodrigues CMP</searchLink>; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370711%22">Experimental and molecular pathology</searchLink> [Exp Mol Pathol] 2026 Mar; Vol. 145, pp. 105013. <i>Date of Electronic Publication: </i>2025 Dec 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>0370711 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-0945 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200144800%22">00144800 </searchLink><i>NLM ISO Abbreviation: </i>Exp Mol Pathol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41352234
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.yexmp.2025.105013
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 105013
    Titles:
      – TitleFull: miR-21-5p dysregulation is associated with gut microbiota dysbiosis and pro-oncogenic markers in primary sclerosing cholangitis with concomitant inflammatory bowel disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Santos AA
      – PersonEntity:
          Name:
            NameFull: Pires D
      – PersonEntity:
          Name:
            NameFull: Marques V
      – PersonEntity:
          Name:
            NameFull: Alesina N
      – PersonEntity:
          Name:
            NameFull: Rodrigues PM
      – PersonEntity:
          Name:
            NameFull: Bravo AC
      – PersonEntity:
          Name:
            NameFull: Gouveia C
      – PersonEntity:
          Name:
            NameFull: Saraiva S
      – PersonEntity:
          Name:
            NameFull: Correia L
      – PersonEntity:
          Name:
            NameFull: Crespo R
      – PersonEntity:
          Name:
            NameFull: da Silva JP
      – PersonEntity:
          Name:
            NameFull: Cravo M
      – PersonEntity:
          Name:
            NameFull: Banales JM
      – PersonEntity:
          Name:
            NameFull: Torres J
      – PersonEntity:
          Name:
            NameFull: Rodrigues CMP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1096-0945
          Numbering:
            – Type: volume
              Value: 145
          Titles:
            – TitleFull: Experimental and molecular pathology
              Type: main
ResultId 1